Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Study

The impact of an electronic alert to reduce the risk of co-prescription of low molecular weight heparins and direct oral anticoagulants.

Brown A, Cavell G, Dogra N, et al. The impact of an electronic alert to reduce the risk of co-prescription of low molecular weight heparins and direct oral anticoagulants. Int J Med Inform. 2022;164:104780. doi: 10.1016/j.ijmedinf.2022.104780

Save
Print
July 6, 2022
Brown A, Cavell G, Dogra N, et al. Int J Med Inform. 2022;164:104780.
View more articles from the same authors.

Alert fatigue and subsequent overrides are known contributors to preventable adverse events particularly for high-risk drug-drug interactions. Researchers assessed prescribers’ actions following an alert for new prescriptions of Low Molecular Weight Heparins (LMWHs) to patients currently prescribed Direct Acting Anticoagulants (DOACs). More than half of the alerts were overridden but were appropriate and justified in most cases.

Save
Print
Cite
Citation

Brown A, Cavell G, Dogra N, et al. The impact of an electronic alert to reduce the risk of co-prescription of low molecular weight heparins and direct oral anticoagulants. Int J Med Inform. 2022;164:104780. doi: 10.1016/j.ijmedinf.2022.104780

Related Resources From the Same Author(s)
Related Resources